Well, the Intel infringement suit obviously gives us something to hope for, since there really isn't anything else. We will obviously either sink or swim based on the outcome. In the meantime, while the lawyers are handling things, what is the team doing?
I can't help but look back at that 2010 shareholder letter and see the following:
On May 11, 2010, Health Discovery Corporation was awarded the prestigious MICO Award for our intellectual property portfolio. The word “mico” is Latin for “to shine.” Unbeknownst to the Company, San Francisco, Calif.-based MDB Capital Group, LLC, spent millions of dollars and hours creating PatentVest, a proprietary intellectual property analytical tool. MDB Capital rigorously analyzed the intellectual property portfolios of 1,600 publicly-traded, small cap companies to determine which ones had the most valuable and disruptive technology. Health Discovery Corporation was honored to be chosen by MDB Capital as the recipient of their MICO award.
It's amazing to me that HDC has the 'disruptive technology' and, based on the USPTO decision in early 2019, is the sole owner of SVM-RFE world-wide. Yet, we can easily see the enormous degree to which companies are using it to their advantage, generating revenues, and laughing in our faces, but there is one company that for some strange reason isn't using it. Guess what company that is? HDC, of course.
How is it even remotely possible that HDC hasn't lined up even a single arrangement whereby we get royalties, or capitalize on products that we supposedly already largely developed (ie, the prostate test)? How can this development not be a significant priority for the company? Perhaps because shareholder value is not part of the equation. It appears that the team has positioned itself for significant personal reward, and has a goal of a one-time windfall before exiting quietly out the back door.
To say it's a disappointment is an understatement.
